This technology includes a novel vaccine for forming autoantibodies against apoC-III, a plasma enzyme that inhibits lipolysis. The vaccine can possibly be used to treat patients with high triglycerides and are at risk for pancreatitis and cardiovascular disease. This disclosure describes an ApoC3 immunogen that includes an antigenicApoC3 peptide linked to a bacteriophage virus-like-particle (VLP) immunogenic carrier.
This technology includes monoclonal antibodies (mAb) that specifically and with high affinity bind the final complement components C3dg and C3d (subsequently referred to as C3d), which can be used to kill tumor cells that carry C3d on their cell surface. We show that tumor cells of patients treated with the therapeutic anti-CD20 mAb ofatumumab carry C3d on the cell surface and can bind and be killed by addition of anti-C3 mAbs. In contrast, further addition of more ofatumumab has only minimal effects.
This technology includes an IgA antibody, specifically designed to target the receptor binding domain of SARS-CoV-2, the virus causing COVID-19. Administered intranasally, this antibody has potential neutralizing activity, aiming to prevent COVID-19. IgA, an antibody class present in mucosal areas, plays a crucial role in immune defense at the initial site of viral infection. The primary application of this technology is envisioned as a therapeutic nasal spray, intended to prevent SARS-CoV-2 infection, particularly in high-risk populations.
This technology includes antibodies for TMC1 protein as a treatment for hearing loss. TMC1 is one of the common genes causing hereditary hearing loss. Our laboratory used synthetic peptides corresponding to the TMC1 protein to immunize rabbits. The resulting antisera were shown to bind to TMC1 protein expressed in heterologous expression systems. TMC1 protein is required for the transduction of sound into electrical impulses in inner ear sensory cells.
This technology includes an antibody that enables the identification and isolation of the protein and protein partners of Vangl2 for application by western blotting, immunoprecipitation and immunocytochemistry. Because planar cell polarity signaling disruption leads to direct or indirect pathologies including malformation of the neural tube, mental retardation, disruption of sensory functions (hearing, balance, vision), cancers (polykystic kidneys disease), or cardiac
This technology includes a bacterial strain derived from BL21 (ED3) CodonPlus Competent Cells containing an expression vector for human POLR2C gene for research purposes. The bacterial strain can be used to produce the full-length human RNA polymerase II subunit, RPB3 protein, which can be in turn isolated and purified.
This technology includes identified members of the mouse cytochromes P450 CYP2J subfamily and antibodies to them for P450 expression studies and metabolism research. Recombinant proteins of the CYP2J subfamily members have also been expressed. The CYP2J subfamily members have a wide tissue distribution and may be useful as model systems for studies of cardiovascular disease, drug metabolism, and toxicity.
This technology includes six human monoclonal antibodies (mAbs) that target tumor antigens derived from the CT-RCC HERV-E (human endogenous retrovirus type E) to generate Chimeric Antigen Receptor (CAR) T cells to treat patients with advanced clear cell renal cell carcinoma (ccRCC). These mAbs were identified from Adagene Inc’s human antibody phage library, and data show that majority of these mAbs only bind to CT-RCC HERV-E+ ccRCC cells, which express TM but not CT-RCC HERV-E non-expressing ccRCC cells nor non-RCC cells.
This technology includes anti-PSMA antibody labeled with 177Lu, which has shown to be an effective treatment for prostate cancer. Several small molecules targeting PSMA were also evaluated in prostate cancer patients labeled with betta emitters such as 177Lu. The most common one is 177Lu-PSMA-617 which is under clinical evaluation in many countries. Usual treatment in patients in most clinical trials was composed of up to 3 cycles of 177Lu-PSMA-617.